Home Companies Catalysts Deep Dives
Jakavi ruxolitinib APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaOncology
Launch2011-11-16
US LOE2027-12-01
Peak Sales Est$1200M
Formulations[{"id":"jakavi-oral","doses":"5mg, 10mg, 15mg, 20mg tablets","route":"Oral","setting":"PATIENT_SELF"
Companies
NVS (ORIGINATOR)100%
Mechanism: JAK1/2 inhibitor
Expert: Selective inhibitor of Janus kinases 1 and 2, reducing myeloproliferative signaling
Everyday: Blocks enzymes that drive abnormal blood cell production
Targets: ["JAK1","JAK2"]
Revenue History
PeriodRevenue ($M)
2024$1,850M
2025$1,920M
Programs (1)
IndicationStageKey StudyRegional Status
Polycythemia veraAPPROVEDRESPONSE[{"stage":"APPROVED","region":"US","approval_date":"2014-12"}]
Notes
JAK1/2 inhibitor. First-in-class for myelofibrosis. Mature franchise.
Data from Supabase · Updated 2026-03-24